INGENUS PHARMS LLC
GenericsINGENUS PHARMS LLC is a generic drug manufacturer focused on Oncology, Cardiovascular, Neurology.
INGENUS PHARMS LLC's Key Drugs
INGENUS PHARMS LLC's core commercial portfolio centers on BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE, spanning Oncology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
INGENUS PHARMS LLC's Recent FDA Approvals
INGENUS PHARMS LLC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
INGENUS PHARMS LLC's Therapeutic Areas
INGENUS PHARMS LLC's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
INGENUS PHARMS LLC's Top Competitors
INGENUS PHARMS LLC's closest competitors by therapeutic-area and drug-target overlap include AbbVie, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
INGENUS PHARMS LLC Pipeline Snapshot
Active clinical trials for INGENUS PHARMS LLC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (0)
Company Info
- First Approval
- 1996-09-27
- Latest
- 2026-06-11
- Applications
- 60